Literature DB >> 2890684

Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma.

M Mannelli1, M L De Feo, M Maggi, C Pupilli, G Opocher, T Valenza, E Baldi, M Serio.   

Abstract

In the present paper we report our experience on the utility of basal plasma catecholamine (CA) measurement and of the clonidine-suppression test in the diagnosis of pheochromocytoma. Basal noradrenaline (NA) and adrenaline (A) were assayed in plasma samples of 27 subjects affected by pheochromocytoma. When compared to basal values obtained in hypertensive patients without pheochromocytoma, one or both the CA resulted pathologically elevated in all patients except one. The response to the clonidine-suppression test was evaluated in 41 hypertensive patients suspected of having a pheochromocytoma measuring plasma NA and A in basal conditions and 2 and 3 h after oral administration of 300 micrograms clonidine. Extensive laboratory and instrumental findings confirmed the presence of pheochromocytoma only in 12 patients. Among the other 29 patients basal plasma CA resulted higher than normal in 4 patients. In patients without pheochromocytoma clonidine induced a significant fall in both NA and A plasma levels. The decrease in NA was observed in each patient. The 12 patients with pheochromocytoma showed a pathological elevation of one or both the CA. In this group clonidine did not significantly suppress plasma CA. The individual responses were extremely variable. Our data confirm the validity of plasma CA measurement as a diagnostic tool for the diagnosis of pheochromocytoma. The results of the clonidine-suppression test were generally confirmatory of the basal CA plasma values but in the 4 hypertensive patients without pheochromocytoma who showed basal plasma CA higher than normal clonidine resulted a useful tool in excluding the presence of pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890684     DOI: 10.1007/BF03348153

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

1.  CLINICAL FEATURES, DIAGNOSIS AND TREATMENT OF PHEOCHROMOCYTOMA: A REVIEW OF 76 CASES.

Authors:  R W GIFFORD; W F KVALE; F T MAHER; G M ROTH; J T PRIESTLEY
Journal:  Mayo Clin Proc       Date:  1964-04       Impact factor: 7.616

2.  Studies on catecholamines, renin and aldosterone following Catapresan (2-(2,6-dichlor-phenylamine)-2-imidazoline hydrochloride) in hypertensive patients.

Authors:  B Hökfelt; H Hedeland; J F Dymling
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

Review 3.  Phaeochromocytoma.

Authors:  P S Sever; J C Roberts; M E Snell
Journal:  Clin Endocrinol Metab       Date:  1980-11

4.  Clonidine-suppression test for diagnosis of pheochromocytoma.

Authors: 
Journal:  N Engl J Med       Date:  1982-01-07       Impact factor: 91.245

5.  Prostacyclin and thromboxane A2 formation in response to adrenergic stimulation in humans: a mechanism for local control of vascular response to sympathetic activation?

Authors:  G G Serneri; G Masotti; G F Gensini; L Poggesi; R Abbate; M Mannelli
Journal:  Cardiovasc Res       Date:  1981-05       Impact factor: 10.787

6.  Activation of the central pathway of the baroreceptor reflex, a possible mechanism of the hypotensive action of clonidine.

Authors:  G Haeusler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

7.  Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications.

Authors:  E L Bravo; R C Tarazi; R W Gifford; B H Stewart
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

8.  Catecholamine suppression testing in patient with phaechromocytoma and normal plasma catecholamine levels.

Authors:  P D Levinson; B K Lance; A A Kowarski; B P Hamilton
Journal:  Lancet       Date:  1983-05-28       Impact factor: 79.321

9.  Clonidine-suppression test in epinephrine secreting pheochromocytoma: report of a case.

Authors:  A G Dupont; P Vanderniepen; E Gerlo; G Somers; L Vanhaelst; P in't Veld; W Gepts; R Sacre; R O Six
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

10.  Alpha-2 adrenergic receptor sensitivity and the mechanism of action of antidepressant therapy. The effect of long-term amitriptyline treatment.

Authors:  D S Charney; G R Heninger; D E Sternberg
Journal:  Br J Psychiatry       Date:  1983-03       Impact factor: 9.319

View more
  5 in total

Review 1.  Diagnosis and management of pheochromocytoma during pregnancy.

Authors:  M Mannelli; D Bemporad
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

Review 2.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

3.  Unusual association of adrenal pheochromocytoma and para-aortic neurofibroma in pregnancy.

Authors:  A Moretti; M Minuto; P Berti; G P Bernini; M Mannelli; P Miccoli
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

4.  A nonsecreting pheochromocytoma presenting as an incidental adrenal mass. Report on a case.

Authors:  M Mannelli; C Pupilli; R Lanzillotti; L Ianni; A Amorosi; G Credi; C Pratesi
Journal:  J Endocrinol Invest       Date:  1993-11       Impact factor: 4.256

5.  The association between systolic blood pressure reduction during clonidine suppression testing and the decrease in plasma catecholamines and metanephrines.

Authors:  Tiran Golani; Boris Fishman; Yehonatan Sharabi; Yael Olswang-Kutz; Avshalom Leibowitz; Ehud Grossman; Gadi Shlomai
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-03       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.